#USA #Salt Lake City #Lipocine #LPCN 1154 #postpartum depression

Lipocine Announces Virtual R&D Investor Event Focused on LPCN 1154 for Postpartum Depression

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company based in Salt Lake City, is poised to lead a virtual research and development investor event on July 9, 2025. This significant gathering aims to bring attention to LPCN 1154 (marketed as BRLIZIO™), a novel therapeutic option currently under development for the treatment of postpartum depression (PPD).

The event, scheduled to commence at 11:00 AM ET, will feature leading physician Dr. Kristina M. Deligiannidis from Zucker Hillside Hospital, New York, who is an expert in mood disorders and their implications for maternal and infant health. She will join Lipocine’s management team to delve into the pressing needs in the current treatment landscape for PPD, a condition that affects a substantial number of new mothers.

Understanding Postpartum Depression

PPD is a serious mood disorder that can emerge during pregnancy or within the first month post-delivery. It is characterized by a range of debilitating symptoms such as persistent sadness, anxiety, fatigue, and significant difficulty in bonding with the newborn. The condition impacts not only the well-being of the mother but also poses risks to both maternal and infant health outcomes. Given the hormonal changes occurring during and after pregnancy, women may experience heightened vulnerability to mood disorders.

Effective treatment options for PPD are imperative because timely intervention can enhance the quality of life for mothers and their families. LPCN 1154 aims to address this critical need by providing a rapid-response oral treatment alternative, designed for outpatient use.

LPCN 1154: Innovative Potential

LPCN 1154 is a bioidentical formulation of brexanolone, a naturally occurring neuroactive steroid that acts as a modulator of GABA receptors in the brain. This formulation stands out for its rapid onset of action, with a projected treatment duration of 48 hours—making it an attractive first-line option for patients exhibiting acute symptoms of PPD. The goal is to alleviate distressing symptoms effectively and safely, minimizing risks particularly in breastfeeding mothers.

During the event, the Lipocine team will share updates on ongoing clinical programs, including crucial developments associated with a Phase 3 registrational study anticipated to produce results in the second quarter of 2026. A live Q&A session will follow the presentations, allowing stakeholders to engage directly with experts in the field.

Dr. Kristina M. Deligiannidis: Expert Insights

Dr. Deligiannidis holds a prominent role in women's behavioral health at Zucker Hillside Hospital and has extensive experience in psychiatric research related to reproductive health. Her work focuses on the intersection of hormonal changes and mental health, particularly during perinatal periods. She has been instrumental in leading clinical trials that contributed to the FDA approval of rapid-acting antidepressants for postpartum depression.

As a member of several distinguished professional organizations and editorial boards of scientific journals, Dr. Deligiannidis is well-equipped to share valuable insights into the challenges and advancements in treating PPD. Her ongoing research delves into the biological and neurophysiological underpinnings of perinatal mood disorders.

Importance of the Upcoming Event

This investor event marks a significant opportunity for stakeholders, investors, and healthcare professionals to remain informed about Lipocine's strategic initiatives in addressing unmet medical needs in women's health. With the focus firmly on LPCN 1154, attendees will gain knowledge on the latest scientific advancements, regulatory updates, and therapeutic potential in the realm of postpartum mental health.

To participate in this important discussion, registration is now open, and interested individuals can secure their spots by following the registration link provided by Lipocine. This event not only presents an opportunity to understand Lipocine’s innovative approach but also the broader implications for maternal healthcare.

With ongoing efforts to address perinatal mood disorders through groundbreaking research and innovation, Lipocine stands at the forefront of a crucial area in women's health that warrants greater attention and actionable solutions.